Suppr超能文献

坎利酮与人子宫胞质溶胶中雌激素和孕激素受体的相互作用。

The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.

作者信息

Fernandez M D, Carter G D, Palmer T N

出版信息

Br J Clin Pharmacol. 1983 Jan;15(1):95-101. doi: 10.1111/j.1365-2125.1983.tb01470.x.

Abstract

1 Canrenone, the major active metabolite of spironolactone, decreased [3H]-progesterone binding to isolated uterine cytosolic progesterone receptors. The inhibition was concentration-dependent. 2 Canrenone did not alter [3H]-oestradiol binding to isolated uterine cytosolic oestrogen receptors. 3 Canrenone inhibition of progesterone binding to isolated cytosolic receptors was strictly competitive: Kd (apparent dissociation constant for progesterone binding) was increased in a concentration-dependent manner by canrenone, whereas Bmax (maximal number of progesterone binding sites/mg cytosolic protein) was unaltered. There was marked cooperativity in progesterone binding at high canrenone and low progesterone concentrations. The implication is that canrenone alters the subunit interaction of the receptor protein. 4 Kd for progesterone was 3.2 X 10(-9)M. Ki (the inhibition constant for canrenone with respect to progesterone binding) was 300 X 10(-9)M. Reports in the literature suggest that, following spironolactone administration, canrenone may rise to concentrations sufficiently high to inhibit progesterone binding. This action may contribute to the effect of spironolactone in inducing menstrual disturbances in female patients.

摘要
  1. 坎利酮是螺内酯的主要活性代谢产物,它能降低[³H] - 孕酮与分离的子宫胞质孕酮受体的结合。这种抑制作用呈浓度依赖性。2. 坎利酮不会改变[³H] - 雌二醇与分离的子宫胞质雌激素受体的结合。3. 坎利酮对孕酮与分离的胞质受体结合的抑制作用是严格竞争性的:坎利酮使Kd(孕酮结合的表观解离常数)以浓度依赖性方式增加,而Bmax(每毫克胞质蛋白中孕酮结合位点的最大数量)未改变。在高坎利酮浓度和低孕酮浓度下,孕酮结合存在明显的协同性。这意味着坎利酮改变了受体蛋白的亚基相互作用。4. 孕酮的Kd为3.2×10⁻⁹M。Ki(坎利酮对孕酮结合的抑制常数)为300×10⁻⁹M。文献报道表明,服用螺内酯后,坎利酮可能会升高到足以抑制孕酮结合的浓度。这种作用可能有助于解释螺内酯对女性患者月经紊乱的影响。

相似文献

2
Interaction of spironolactone with oestradiol receptors in cytosol.
J Endocrinol. 1980 Mar;84(3):371-9. doi: 10.1677/joe.0.0840371.
5
Tissue specific effects of progesterone on progesterone and estrogen receptors in the female urogenital tract.
J Steroid Biochem. 1989 Jan;32(1A):35-9. doi: 10.1016/0022-4731(89)90010-1.

引用本文的文献

本文引用的文献

3
SPIRONOLACTONE THERAPY AND GYNECOMASTIA.
JAMA. 1965 Jul 12;193:163-4. doi: 10.1001/jama.1965.03090020077026.
6
The aldosterone blocking effects of spirolactones.螺内酯的醛固酮阻断作用。
Jpn J Pharmacol. 1962 Mar;11:77-87. doi: 10.1254/jjp.11.77.
7
A novel use of spironolactone: treatment of hirsutism.
J Clin Endocrinol Metab. 1980 Sep;51(3):429-32. doi: 10.1210/jcem-51-3-429.
8
Interaction of spironolactone with oestradiol receptors in cytosol.
J Endocrinol. 1980 Mar;84(3):371-9. doi: 10.1677/joe.0.0840371.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验